SCHEMBL30248570

SCHEMBL30248570

O=C(NCc1ccc2c(c1)N(c1ccccc1)CCS2)Nc1ccc2cc[nH]c2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.44
ROCK2 O75116 2/20 0.44
MAPT P10636 4/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
GAA P10253 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPK1 P28482 1/20 0.41
DDB1 Q16531 2/20 0.40
CRBN Q96SW2 2/20 0.40
KDM4E B2RXH2 1/20 0.39
NAMPT P43490 1/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
NLRP3 Q96P20 2/20 0.39
ROCK1 Q13464 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25028038 1.00 FAAH (0.44) FAAHROCK2MAPTMEN1KMT2A
SCHEMBL25028041 0.95 ROCK2 (0.44) FAAHROCK2MAPTMEN1KMT2A
SCHEMBL30895162 0.95 ROCK2 (0.44) FAAHROCK2MAPTMEN1KMT2A
SCHEMBL23769050 0.89 FAAH (0.41) FAAHMAPTMEN1KMT2ANPC1
SCHEMBL29979338 0.89 FAAH (0.41) FAAHMAPTMEN1KMT2ANPC1
SCHEMBL25028529 0.87 MAPT (0.52) FAAHROCK2MAPTSMN1; SMN2KDM4E
SCHEMBL30248448 0.87 MAPT (0.52) FAAHROCK2MAPTSMN1; SMN2KDM4E
SCHEMBL29978704 0.85 ESR1 (0.40) FAAHMAPTMEN1KMT2ANPC1
SCHEMBL23768831 0.85 ESR1 (0.40) FAAHMAPTMEN1KMT2ANPC1
SCHEMBL30895152 0.83 MAPT (0.46) FAAHROCK2MAPTSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118019738-A Small molecule urea derivatives as STING antagonists 库拉德夫制药私人有限公司 2024-05-10 CN claimed
EP-4384268-B1 SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS CURADEV PHARMA PVT LTD (IN) 2026-03-18 EP disclosed
US-20240360119-A1 SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS CURADEV PHARMA PVT. LTD. (IN) 2024-10-31 US disclosed
EP-4384268-A1 SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS Curadev Pharma Pvt. Ltd. (IN) 2024-06-19 EP disclosed
CN-118019738-A Small molecule urea derivatives as STING antagonists 库拉德夫制药私人有限公司 2024-05-10 CN disclosed
WO-2023017452-A1 SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS CURADEV PHARMA PVT. LTD. (IN) 2023-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360119-A1 SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS STING1, CGAS, SSB FAAH 1194/4885ROCK2 1718/4885MAPT 2509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.